Research programme - GAIM monomers - NeuroPhage PharmaceuticalsAlternative Names: NPT-005
Latest Information Update: 16 Jul 2016
At a glance
- Originator NeuroPhage Pharmaceuticals
- Developer Proclara Biosciences
- Mechanism of Action Amyloid beta-protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Amyloidosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Amyloidosis in USA
- 13 May 2013 Early research in Amyloidosis in USA (unspecified route)